Twelve of the top 20 Big Pharmas could soon outsource 100 per cent of their clinical trial work using one of two strategic partnering models according to a speaker at contract research industry conference in Lyon, France yesterday.
Quintiles will bring its commercial activities within the Asia-Pacific region in-house after selling its share of jointly established company Invida Group.
Endeavour Specialty Chemicals has launched a novel range of pyridinyl thioureas designed to cater for growing pharmaceutical industry interest in the development of prion disease treatments.
The ICH has approved a revision to its genotoxicity testing and data interpretation guidelines that it says will improve risk assessment and reduce the number of animals used during preclinical development.
The USP has forged closer bonds with the Chilean Pharmacopoeia Foundation (CPF) in the latest of a series of agreements with regional drug quality groups.
Warnex’ pharmaceutical quality control (QC) contracting business continued to struggle in Q3, offsetting gains made by its trial laboratory services unit.
Almac says growing demand for non-GMP manufacturing work rather than competition was the key driver for expansion of its product development services business.
Bristol-Myers Squibb has penned a technology transfer agreement with the Brazilian government in what it says is a bid to increase access to HIV drug Reyataz (atazanavir sulfate) in the area.
Indian excipient manufacturers could have a new trade body in early 2012 according to an international industry organisation asked to set up an association in the country.
Pfizer will sell Mylan its dry-powder inhaler delivery system in an agreement set to pit the generics firm against UK drug major GlaxoSmithKline (GSK).
BioClinica says increasing interest in CNS disorders will drive the imagining sector; and predicts that pharmas and CROs will want integrated EDC in two years.
Recapturing customers will not be easy for Albany Molecular Research (AMRI) after the problems at its manufacturing plant in Burlington, Massachusetts according to an analyst.
Pharma sector corporate social responsibility (CSR) reporting has increased dramatically in recent years according to a new report that argues such activity enhances financial value.
Asking the right questions is key to giving pharmaceutical industry contract managers the information they need to select the best CRO partners according to the team behind a new performance assessment project.
Charles River Laboratories (CRL) continued to experience low demand for preclinical services in Q3, while Covance's early-phase business saw revenue growth.
BASF will start producing synthetic menthol next year using a new method that, it claims, offers significant quality and supply advantages for drug and food manufacturers.
